Treatment of glucocorticoid-induced protein wasting

Impact of growth hormone and androgens on protein metabolism in subjects with polymyalgia rheumatica and inflammatory arthritis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000642684

Enrollment

Registered

2005-10-14

Start date

2004-07-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary purpose is to determine whether growth hormone and androgens alter protein metabolism in a way that will reduce protein loss in long-term glucocorticoid users. If so they may be a potential therapy to reduce the skin thinning and muscle weakness that occurs during longterm glucocorticoid use.

Interventions

Two weeks of growth hormone and androgens (testosterone for men, DHEA for women) alone and in combination.

Study design

Allocation

Non-randomised trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Receiving prednisone for > 6 months for polymyalgia rheumatica or inflammatory arthritis.

Exclusion criteria

Diabetes mellitus, cancer, liver or kidney failure.

Outcome results